Chronic Care: Medicines & Medical Devices

Own the medicines and medical devices used repeatedly to manage chronic illness, rather than concentrating on a single drug platform or development pipeline. Lilly's recent company-specific share-price strength supports renewed attention to chronic-care franchises, although it is not evidence of a new clinical breakthrough. The basket pairs established drug businesses with diabetes monitoring, cardiovascular intervention and implanted-device franchises; reimbursement pressure and product competition remain key risks. Catalysts: - 2026-10-20 LLY: Eli Lilly shares climb 3.6% as its GLP-1 franchise remains in focus (https://www.marketbeat.com/instant-alerts/price-eli-lilly-and-company-nyse-lly-shares-climb-36-still-a-buy-2026-10-20/) Launch basket (equal weight): MDT, LLY, ABBV, AMGN, JNJ, ABT, DXCM, BSX Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.